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Abstract
The heat shock protein, Hsp70, has been shown to play an important role in tumour immunity.
Vaccination with Hsp70-peptide complexes (Hsp70-PCs), isolated from autologous tumour cells,
can induce protective immune responses. We have developed a novel method to identify synthetic
mimic peptides of Hsp70-PCs and to test their ability to activate T-cells. Peptides (referred to as
"recognisers") that bind to Hsp70-PCs from the human breast carcinoma cell line, MDA-MB-231,
were identified by bio-panning a random peptide M13 phage display library. Synthetic recogniser
peptides were subsequently used as bait in a reverse bio-panning experiment to identify potential
Hsp70-PC mimic peptides. The ability of the recogniser and mimic peptides to prime human
lymphocyte responses against tumour cell antigens was tested by stimulating lymphocytes with
autologous peptide-loaded monocyte-derived dendritic cells (DCs). Priming and subsequent
stimulation with either the recogniser or mimic peptide resulted in interferon-γ (IFN-γ) secretion
by the lymphocytes. Furthermore, DCs loaded with Hsp70, Hsp70-PC or the recogniser or the
mimic peptide primed the lymphocytes to respond to soluble extracts from breast cells. These
results highlight the potential application of synthetic peptide-mimics of Hsp70-PCs, as modulators
of the immune response against tumours.
Background
Both T- and B-cell immune responses to tumour-derived
proteins have been identified in many cancer patients,
however the responses are generally insufficient to result
in tumour clearance. One of the challenges in cancer treat-
ment is to enhance this anti-tumour immune response,
perhaps by identifying novel tumour antigens with a
higher immunogenic potential. Such antigens have the
potential to be tumour biomarkers in serological testing
and targets in anti-tumour vaccine development. Cur-
rently there are many serologically defined protein
tumour markers known and in some cases the corre-
sponding peptide sequences have been identified [1].
Promising results have been observed following vaccina-
tion with antigenic peptides derived from the 'cancer-tes-
tis' antigen, MAGE-3, NY-ESO-1 and the melanocyte
differentiation antigens Melan-A/MART-1/tyrosinase and
gp100 [2,3].
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Tumour-derived heat shock protein (Hsp) preparations
have been shown to elicit anti-tumour immune responses
in both mice and man [4]. In mice, immunisation with
tumour cell extracts was shown to confer immuno-protec-
tion against a subsequent challenge with the same
tumour. When these extracts were fractionated, the stress
proteins, Hsp70 and gp96 were identified as the protec-
tive agents [5-7]. Further experiments showed that it is the
peptides complexed with these proteins that are responsi-
ble for the generation of tumour-specific immune
responses [8-11].
Recent studies have shown that chaperones such as heat
shock proteins gp96, Hsp90, Hsp70 and calreticulin can
be taken up by dendritic cells by receptor mediated endo-
cytosis, where they enter the MHC class I antigen presen-
tation pathway and are cross-presented to T-cells [12-19].
Additionally, both gp96 and highly purified Hsp70 have
been shown to directly stimulate monocytes and dendritic
cells to secrete cytokines, in a manner similar to LPS. They
also up-regulate HLA and other co-stimulatory molecules,
thereby enhancing the presentation of any associated
chaperoned peptides to the T-cells [20]. This dual func-
tion of 'adjuvant-cum-antigen pool', make gp96- and
Hsp70-peptide complexes, (referred to as gp96-PCs and
Hsp70-PCs), good candidates for tumour vaccines. In this
regard, some very exciting and crucial clinical trials to
stimulate immune responses using autologous gp96-PCs
and Hsp70-PCs purified from resected tumours are ongo-
ing with some encouraging outcomes in patients with
melanoma [21]. Autologous gp96-PCs are currently being
tested for the treatment of lymphoma, renal cell carci-
noma, colorectal, gastric, pancreatic and breast cancers
while Hsp70-PCs are being tested for the treatment of
chronic myelogenous leukemia (CML; Antigenics Inc.,
New York, NY).
A novel approach to the development of tumour vaccines
has been the isolation of peptide mimics to epitopes of
known oncogene products or tumour specific antigens. A
classical example of this is the anti-idiotype antibody
105AD7 which inhibits the binding of the monoclonal
antibody 791T/36 to its antigen TAA gp72 [22,23]. Subse-
quent studies have revealed that 105AD7 mimics the
epitope of a widely expressed cellular protein CD55 [24].
A large number of anti-idiotype antibodies have been
identified and many have been used with or without
modifications in cancer immunotherapy [25-27]. Bio-
panning of peptide phage display libraries using antibod-
ies to known tumour antigens have led to the identifica-
tion of mimic epitopes (mimotopes) [28-34]. Such
selected 'mimotopes' can elicit highly specific humoral
immune responses against the peptides and/or the origi-
nal tumour antigen. Although the baits used in the above
studies were relatively pure, it is now well established that
successive rounds of rigorous bio-panning will select/
enrich and amplify ligands even from a mixture of baits.
For example, intravenously administered phage display
library has been successfully used for in vivo bio-panning
in certain animal model systems to identify tissue-specific
peptide ligands [35,36] and see refs. [37,38] for reviews.
We have devised a novel approach to generate peptides
that mimic the antigenicity of tumour cell-derived Hsp70-
PCs, first by screening a random peptide M13 phage dis-
play library using as bait Hsp70-PCs extracted from the
human breast cancer cell line, MDA-MB-231 to identify
putative Hsp70-PC binding phages (recogniser phages).
After several rounds of bio-panning, a number of 'recog-
niser peptides' were identified. Subsequently, we used
selected synthetic 'recogniser peptides' as baits in a
'reverse' bio-panning experiment to identify phages that
interact with the recogniser peptides. Our hypothesis sug-
gests that such phages may display peptides that are puta-
tive structural mimics of the Hsp70-PCs. One of the
'recogniser peptides' used in the reverse bio-panning led
to the enrichment of a single class of phages all coding for
the same mimic peptide. We tested the ability of this
mimic peptide to stimulate human lymphocytes, either
directly or presented by autologous monocyte-derived
dendritic cells (DCs). Our results show that CD14- PBMCs
primed with the mimic peptide loaded onto DCs, produce
IFN-γ upon a second stimulation with the same peptide.
Furthermore, CD14-  PBMCs primed with DCs loaded
with Hsp70-PC from MDA-MB-231 cells in vitro, pro-
duced IFN-γ upon subsequent stimulation with the mimic
peptide. Our results also show that CD14- PBMCs primed
with DCs loaded with the mimic peptide, produce IFN-γ
when challenged with soluble cell extracts from either
MDA-MB-231 (tumourigenic) or MCF-12A (non-tumour-
igenic) breast cell lines. These results suggest that the syn-
thetic mimic peptide immunologically resembles
peptides present in the protein extracts from breast cell
lines and more specifically resembles peptides complexed
with Hsp70. Thus, the approach outlined in this paper for
the detection of Hsp70-PC mimics should prove
extremely useful in the identification of tumour-specific
peptide mimics with immune modulatory properties.
Materials and methods
Cell lines
The breast cancer cell line MDA-MB-231 was a generous
gift from Dr. Boucher-Hayes, Beaumont Hospital, Dublin,
and was grown in RPMI-1640 supplemented with 10%
foetal calf serum (FCS). The normal breast cell line MCF-
12A was purchased from ATTC-LGC (Teddington, U.K)
and grown in supplemented DMEM as recommended by
the supplier. Media also contained 2 mM L-glutamine, 1×
antibiotic/antimycotic solution (Sigma Chemical Co.)
and 100 U/mL nystatin suspension.Journal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
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Cell extracts and purification of Hsp70 and Hsp70-PCs
To prepare tumour cell extracts, the MDA-MB-231 or
MCF-12A cells were trypsinised and harvested. Cells were
washed twice in ice-cold PBS and the cell pellets resus-
pended in 1 mL PBS and lysed by 5 freeze/thaw cycles fol-
lowed by sonication. The insoluble material was pelleted
by centrifugation (20,500 × g for 30 min.). The superna-
tants were aliquoted and stored at -20°C. The Hsp70 and
Hsp70-PCs were purified from 108 MDA-MB-231 or MCF-
12A cells as previously described [7]. The purified proteins
were analysed by SDS-PAGE, and immunoblotting using
mouse monoclonal anti-Hsp70 and biotinylated anti-
mouse secondary antibodies (Sigma Chemical Co.) in a
streptavidin-horseradish peroxidase based chemilumines-
cence detection system.
Bio panning and library amplification and selection
Approximately 1011 phage particles from a 12-mer M13
phage display library (PHD-12; New England Biolabs Inc.,
MA) were used for each bio-panning experiment. Approx-
imately 10 µgs of Hsp70-PCs (100 µg/mL) were immobi-
lised in a single well of a 96-well Maxisorb (Nunc-Nalge
Inc.) microtitre plates. The blocking, binding and washing
strategies were carried out as instructed by the manufac-
turer with the following exceptions. We used (a) either 1%
Bovine Serum Albumin (BSA) or casein for blocking non-
specific binding alternating these blocking substrates
between subsequent rounds of bio-panning to prevent
selection of phage recognising the blocking substances,
(b) competitive elution with the bait Hsp70-PCs in
rounds three and four and (c) bio-panning in solution for
rounds two and four, using biotinylated Hsp70-PCs and a
streptavidin matrix to prevent selection of plastic-binding
phages. In the latter case, 10 µg of Hsp70-PCs were bioti-
nylated using NHS-Biotin (Sigma Chemical Co., Poole,
U.K.) according to the manufacturer's instructions and
incubated with 1011 phage particles as recommended by
the manufacturer with either of the blocking reagents. The
Hsp70-PCs bound phage particles were recovered either
through a Streptavidin-agarose (Pierce Chemical Co. ILL)
column or Streptavidin-Dynabeads (Dynal Co., Norway)
followed by washing and competitive elution as described
above. Following each round of bio-panning, the eluted
phages were amplified to high titer according to supplier's
instructions. A subtraction screening using the peptide
depleted Hsp70-PC [7] was performed after the third bio-
panning to remove those phages recognising the Hsp70
portion of the Hsp70-PC bait. The unbound fraction was
amplified and used in the fourth round bio-panning. The
phage particles from the final fourth round eluate were
plated at low density to allow isolation of single phage
clones. The DNA insert from the amplified phage clones
was sequenced and the Hsp70-PCs binding 12-mer recog-
niser peptide sequences were deduced. To identify poten-
tial Hsp70-PCs mimic peptides, the recogniser peptides
(including the tri-Glycine linker) were synthesised (see
below) and used as bait in a similar bio-panning proce-
dure as above with the exception that the subtraction step
with Hsp70 was not included. Special attention was taken
to ensure the binding of the bait peptide to the matrix.
After 4 rounds of bio-panning, the eluted phage display-
ing mimic peptides were analysed as above.
Peptides
The C-terminal amidated peptides, TMG (recogniser),
DSP (mimic), and WHK (mimic), with a three glycine-
spacer arm and with or without an N'-terminal biotin tag
were synthesized at the Advanced Biotechnology Centre
(Imperial College, U.K).
M13 phage ELISA
Biotinylated DSP or TMG peptides (200 pmoles) were
bound to 200 mg streptavidin-coated magnetic beads
(Dynal Co, Norway) according to manufacturer's instruc-
tions. Following blocking with 0.5% BSA and 0.1 mM D-
biotin in PBS, the beads were incubated for three hours
with selected M13 phage clones (1011 pfu) displaying
either the TMG or DSP peptides. Unbound phages were
removed by repeated washing with excess PBS containing
0.05% TWEEN-20 (PBS-Tween). The bound phages were
detected by incubation with HRP conjugated anti-M13
monoclonal antibody (anti-M13-HRP; Amersham Bio-
sciences, UK; 1:2,500) according to suppliers instructions
except that the beads were transferred to wells of a micro-
titer plate prior to colour development. As controls, beads
alone without peptides were processed through the same
procedure.
Isolation of monocytes and lymphocytes and generation of 
immature DCs
Buffy coat packs from healthy female donors were
obtained from the Irish Blood Transfusion Service.
PBMCs were prepared by Lymphoprep (Nycomed, Oslo,
Norway) density gradient centrifugation. Monocytes were
isolated by positive selection of CD14+ cells using CD14
Microbeads (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). Immature DCs (iDCs) were generated by culturing
monocytes for 6 days in RPMI-1640 medium supple-
mented with 10% endotoxin-free foetal calf serum, 2 mM
L-glutamine, 80 U/mL each of penicillin and streptomy-
cin, 2 µg/mL amphotericin B in the presence of 60 ng/mL
recombinant human granulocyte macrophage colony
stimulating factor (GM-CSF) and 150 ng/mL recombinant
human IL-4. Medium and cytokines were replaced every 2
days. The CD14- PBMC, which mainly consist of lym-
phocytes (B cells, T cells, NK cells and NKT cells) were cry-
opreserved for later use as responder cells.Journal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
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In vitro stimulation assay of lymphocytes
Lymphocyte stimulation was performed using a modifica-
tion of a published procedure [39]. Approximately 104
immature dendritic cells (iDCs) were incubated with 100
µl of medium containing 10 µg/mL LPS and peptides (25
µg/mL DSP, TMG or WHK), MDA-231 or MCF-12A cell
extracts (total protein concentration 110 µg/mL in each
case), or Hsp70 or Hsp70-PCs (both at 5 µg/mL) or media
alone. After 24 hour incubation, the cells were pelleted
and the culture media were assayed for IL-12 by ELISA
(see below). The iDCs were resuspended in RPMI, γ-irra-
diated with a dose of 5,000 rads and washed in RPMI. The
irradiated iDCs were incubated with CD14- PBMCs at a
1:10 ratio in a final volume of 100 µL of supplemented
RPMI. After 48 hours incubation, the supernatants were
assayed for IFN-γ by ELISA. These cells (designated as
'primed CD14- PBMCs) were cultured for a further 10 days
in 200 µL of the same media supplemented with human
recombinant IL-2 (25 ng/mL) and with media changes
every 3 days. On day 9, a new batch of iDCs from the same
donor was incubated with peptides, cell extracts or media
alone but in the absence of LPS. After 48 hrs, the culture
supernatants were assayed for IL-12 levels. Following γ-
irradiation and washes, these loaded iDCs were incubated
with the primed CD14-  PBMCs at a ratio of 1:10
(iDC:CD14- PBMCs). After 2 days incubation the culture
supernatants were assayed for IFN-γ content by ELISA.
Measurement of cytokine release
The IFN-γ released by the stimulated CD14-PBMC were
measured by ELISA using antibody pairs (DuoSet human
IFN-γ; R & D Systems, Oxon, UK). IL-12p40 production
by iDCs was detected using DuoSet human IL-12p40 anti-
bodies, R&D Systems).
Results
Identification of recogniser and mimic peptides of Hsp70-
PCs through bio-panning of an M13 phage display library
Protein fractions enriched in Hsp70-PCs were obtained
from MDA-MB-231 cells using ADP-agarose affinity chro-
matography. Western blot analysis using anti-Hsp70 anti-
bodies and Coomassie Blue staining of the corresponding
SDS gel show that the most prominent protein eluted
from the column with ADP is the constitutive (Hsp73)
and/or the inducible (Hsp72) forms of Hsp70 (Fig. 1A
and 1B, lane 3) confirming similar findings by others [7].
To isolate peptides that "recognise" Hsp70-PCs, the col-
umn eluate fraction was used as bait to biopan a random
peptide M13 phage display library. Four rounds of bio-
panning were performed as described in the Materials and
Methods section and as outlined in Figure 2. Three separate
bio-panning experiments were performed using Hsp70-
PCs as bait. In each case, approximately 400–1000 phages
were retained after four rounds of panning. A total of
twenty four phage clones were selected at random for fur-
ther analysis. DNA was isolated from the phages and was
sequenced in order to identify the peptide displayed by
each phage clone. The peptide sequence in each case was
named according to the first three amino acids in their
sequence. As shown in Table 1, a wide variety of peptide
sequences were identified in each bio-panning experi-
ment, some of which were common in two of the three
Purification of Hsp70 and Hsp70-PCs from MDA-MB-231  cells by affinity chromatography Figure 1
Purification of Hsp70 and Hsp70-PCs from MDA-MB-
231 cells by affinity chromatography. Hsp70-peptide 
complexes (Hsp70-PCs) were isolated from whole cell 
extracts of MDA-MB-231 cells using ADP-Agarose. A. 
Coomassie-Blue stained SDS-polyacrylamide gel and B: 
Western blot using anti-Hsp70 antibody. Lane 1: MDA-MB-
231 total cell extract (10 µg), Lane 2: Flow-through from an 
ADP-agarose column (2 µg), Lane 3: Proteins eluted from 
ADP-agarose column with 3 mM ADP (2 µg). Lane 4: Molec-
ular weight markers. C: ELISA to detect the interaction 
between biotinylated TMG and DSP peptides and the corre-
sponding phages. Streptavidin-coated paramagnetic beads 
bound to biotinylated TMG peptide (TMG) or DSP peptide 
(DSP) were incubated with the M13 phage clones displaying 
DSP or TMG respectively. As a control, streptavidin-coated 
beads without the peptides were incubated with M13 phage 
clone displaying the TMG (TMG negative) or the DSP (DSP 
negative) peptides alone. All beads were then incubated with 
anti-M13-HRP antibody. Interactions were detected by 
absorbance at 405 nm using DAB as a substrate.Journal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
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bio-pannings. In one case, the phage displaying the TMG
peptide was selected in all three bio-pannings (Table 1).
To identify phage that can interact with the recogniser
peptides and thus may represent potential structural mim-
ics of the original Hsp70-PCs, a reverse bio-panning was
carried out using synthetic recogniser peptides. Peptides
containing the sequences represented by the NNY, IER
and TMG phages (Table 1) were synthesized and used as
baits. Following four rounds of bio-pannings a group of
phage clones were recovered and their DNAs were
sequenced. The representative peptide sequences in the
enriched phage pool are shown in Table 2. Both IER and
NNY peptides selected a number of phages with different
peptide sequences. Theoretically, these phages should dis-
play structures that 'mimic' the bait used to identify the
corresponding recogniser peptides. Both IER and NNY
bait peptides selected in high proportion a phage display-
ing the peptide SVS. However, subsequent literature
searches revealed that this peptide has previously been
identified in bio-panning experiments using unrelated
baits [40,41]. Unlike the IER and NNY peptides, the TMG
peptide selected a single class of peptide which is desig-
nated DSP (Table 2). Since the TMG peptide was selected
in all three independent bio-panning experiments and
enriched a single potential mimic peptide sequence we
focused our subsequent analysis on the TMG/DSP recog-
niser/mimic pair.
The DSP peptide specifically interacts with phages 
displaying the TMG peptide
The specificity of the interaction between the TMG and
DSP peptides was examined by ELISA (see Materials and
Methods). As shown in Fig 1C, phages displaying the DSP
peptide specifically bind to a synthetic biotinylated TMG
peptide (Fig. 1C, TMG). Conversely, phages displaying the
TMG peptide bind to a synthetic biotinylated DSP peptide
(Fig. 1C, DSP). In the absence of biotinylated peptides, lit-
tle or no detectable signal was obtained following incuba-
tion of either of the phages alone with streptavidin-coated
magnetic beads (Fig. 1C, DSP negative, TMG negative).
Furthermore, in situ histochemical staining revealed that
both the TMG and the DSP peptides display cytoplasmic
staining in MDA-MB-231 cells suggesting that these pep-
tides recognise and interact with cellular components
(data not shown).
The DSP and TMG peptides have immune stimulatory 
properties
We next examined whether TMG, DSP or an unrelated
peptide WHK (Table 2) can stimulate iDCs to release IL-
12 and/or lymphocytes to produce IFN-γ. The iDCs were
incubated with the peptides DSP, TMG or WHK in the
presence or absence of LPS. The culture supernatants were
tested for IL-12 by ELISA. Figure 3A shows that IL-12
secretion was detected only when LPS was included but
Table 1: List of Hsp70-PC (MDA-MB-231 cells) recognising 
phages
Recogniser Peptide Frequency 
(% of total phage 
clones sequenced)
No. of times 
recovered in 
independent screens
TMGFTAPREPHY 10 3
IERPLHESVLAT 16 2
NNYDDISLRARP 22 2
AIPNKLNVWPPH 12 1
TGVSWSVAQPSF 8 1
SQELTQRPYKWH 8 1
TPSYINLXDFIA 8 1
GTSTFNSVPVRD 8 1
KLTFLNYAEVLR 8 1
Schematic outline of bio-panning procedure Figure 2
Schematic outline of bio-panning procedure.Journal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
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not in its absence when iDCs were stimulated with the
peptides alone.
CD14- PBMCs were incubated with TMG, DSP or WHK
peptides either directly in solution or after loading onto
autologous monocyte-derived iDCs. The supernatants
were removed for analysis of IFN-γ production by ELISA
after 2 days. These cells were then cultured for a further 10
days in the presence of IL-2, following which they were re-
stimulated either with the respective peptide in solution
or a second batch of the iDCs from the same donor loaded
with the peptides. After a further 2 days the supernatants
were tested for the presence IFN-γ. The results (Fig. 3B)
show that no IFN-γ was released, either in response to the
first or second stimulation with any of the peptides when
iDCs were excluded. However, CD14- PBMCs responded
albeit weakly to a first stimulation with iDCs loaded with
either DSP or TMG peptides and significantly, not at all to
WHK. Furthermore, when the cells were re-stimulated
with iDCs primed with the corresponding peptides (DSP
or TMG), much higher levels of IFN-γ were produced.
Again, the response to the WHK peptide was weak (Fig.
3B). These results were reproducible in four separate
experiments, in each case using cells from a different
healthy donor and indicate that both the DSP and TMG
peptides are capable of stimulating human lymphocytes
to release IFN-γ, by a mechanism that requires DCs, but
which appears to be independent of IL-12 production.
DCs loaded with Hsp70 or Hsp70-PC from MDA-MB-231 
cells can prime human lymphocytes to respond to MDA-
MB-231 cell extracts
The consecutive stimulation of CD14- cells with DCs, as
described above, was repeated except that different anti-
gens pools were used in the first and second rounds of
stimulation. Lymphocyte activation will only occur if the
DCs present the same or a very similar antigen(s) in the
two stimulations [39]. We first examined the consecutive
stimulation of CD14- cells with Hsp70-PCs and protein
extracts from MDA-MB-231 cells.
Recogniser and Mimic peptides presented by iDCs can stimu- late CD14- PBMCs to secrete IFN-γ secretion Figure 3
Recogniser and Mimic peptides presented by iDCs 
can stimulate CD14- PBMCs to secrete IFN-γ secre-
tion. A. IL-12 production by immature dendritic cells. iDCs 
(+DCs; black bars) were incubated with or without LPS and 
either DSP, WHK or TMG peptides for 24 hrs. as labeled. 
The concentration of IL-12 (pg/mL) in the supernatants was 
determined by ELISA. IL-12 production in the absence of 
iDCs was also determined. B. iDCs were incubated with 
WHK, DSP or TMG peptides. Subsequently, either peptide-
loaded iDCs (+iDCs) or the free peptide in solution (-iDCs), 
were incubated with CD14- PBMCs from the same donor 
[First stimulation; (1) open bars]. These cells were incubated 
with a second batch of iDCs loaded with the same peptide 
[Second stimulation (2); filled bars]. The concentration of 
IFN-γ (pg/mL) in the supernatants of the CD14- PBMCs was 
determined following the first (1) and second (2) stimula-
tions.
Table 2: List of recogniser peptides and corresponding mimic 
peptides
Recogniser Peptides Frequency 
(% total phage clones 
sequenced)
Mimic Peptides
NNYDDISLRARP 46 SVSVGMKPSPRP
18 FHSDWPGXTLTW
9 LHAETRSAMHRT
9 WKHTSQPPRLIF
9 KAXTPVQSASNV
9 RTHDNSWNYTSS
TMGFTAPREPHY 100 DSPQNPKTWKYI
IERPLHESVLAT 32 SVSVGMKPSPRP
15 GLPPYSPHRLAQ
15 NFMESLPRLGMH
15 NAQNYSQQAPRP
15 HGLHQMSGNTKR
8 HPHQPIERQTVQJournal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
Page 7 of 12
(page number not for citation purposes)
CD14- PBMCs were incubated with irradiated autologous
monocyte-derived DCs pulsed with Hsp70, Hsp70-PC or
soluble total protein extracts from MDA-MB-231 cells.
The cells were then cultured for 10 days in the presence of
IL-2, following which they were re-stimulated with iDCs
pulsed with soluble protein extracts from MDA-MB-231
cells. After a further 2 days incubation, supernatants were
tested for IFN-γ production. As shown in Figure 4, CD14-
PBMCs, primed with Hsp70-pulsed iDCs and challenged
with iDCs pulsed with MDA-MB-231 cell extracts (tumour
cell: TC) in the second stimulation [Fig. 4 Hsp70(1)/
TC(2)], produced IFN-γ (pg/mL) levels at 60% and 46%
of that produced by cells primed and challenged with
MDA-MB-231 total cell extracts [TC(1)+TC(2)], in two
individual blood donors respectively. Significantly higher
levels of IFN-γ were secreted when cells were primed with
Hsp70-PC and challenged with iDCs pulsed with TC [Fig.
4 Hsp70-PC(1)/TC(2); 98% and 68% the levels produced
by cells primed and challenged with MDA-MB-231 total
cell extracts in the two donors respectively]. Little or no
IFN-γ was released when CD14- PBMCs received only a
single exposure of iDCs pulsed with TC (Fig. 4; TC(1), nor
when CD14- PBMCs were incubated with iDCs stimulated
with LPS alone for the first stimulation and challenged
with iDCs loaded with the soluble cell extract (data not
shown).
DCs loaded with DSP or TMG peptides can prime human 
lymphocytes to respond to MDA-MB-231 cell extracts
To determine if the mimic peptide DSP resembles any
endogenous peptides or proteins present in the extracts
from MDA-MB-231 tumour cells, the consecutive stimula-
tion of CD14- cells with different antigen pools was per-
formed as described above. CD14- PBMCs primed initially
with iDCs loaded with the DSP peptide and subsequently
stimulated with iDCs loaded with TC extracts secreted
IFN-γ at 56% and 27% the levels produced when CD14-
cells were both primed and stimulated with TC extracts in
donors A and B respectively, [Fig. 5A; DSP(1)+TC(2)].
Lower levels of IFN-γ were produced by CD14- cells stim-
ulated first with TMG and then with TC extracts [Fig. 5A;
TMG(1)+TC(2)]. Little or no IFN-γ was detected when
CD14- PBMCs received only a single exposure to TC [Fig.
5A, TC(1)], nor was IFN-γ produced when PBMCs were
incubated with iDCs stimulated by LPS alone in the first
stimulation and then challenged with iDCs loaded with
TCs in the second stimulation (data not shown).
To determine whether the T cell stimulation by the pep-
tides was tumour cell-specific, the experiment was
repeated but this time using a cell extract from a non-
tumourigenic breast cell line, MCF12A (Fig. 5B non-
tumour cells: NTC). CD14- PBMCs first stimulated with
iDCs loaded with the peptide DSP and then challenged
with NTC total protein extract, produced IFN-γ at 46%
and 32% the levels produced when CD14- cells were both
primed and stimulated with NTC total protein extract in
donors A and B, respectively (Fig. 5B; DSP(1)+NTC(2)).
In contrast, when primed with iDCs loaded with TMG and
stimulated with iDCs loaded with NTC total protein
extract, the relative IFN-γ levels were 6.3% and 28% in
donors A and B respectively (Fig. 5B: TMG(1)+NTC(2)).
There was little detectable IFN-γ produced by cells stimu-
lated by a single exposure to NTC total protein extract [Fig.
5B, NTC(1)], nor when CD14- cells were incubated with
iDCs stimulated by LPS alone in the first stimulation and
then challenged with iDCs loaded with NTCs in the sec-
ond stimulation (data not shown).
iDCs loaded with Hsp70 or Hsp70-PC can prime human 
lymphocytes to respond to DSP peptide
CD14- PBMCs were first stimulated with iDCs pulsed with
the DSP peptide, Hsp70 or Hsp70-PCs and subsequently
stimulated with iDCs pulsed with the mimic peptide DSP.
As shown in Figure 6, CD14- PBMCs from two individual
donors, primed with Hsp70-PCs respond very effectively
to a second stimulation by iDCs loaded with the DSP pep-
tide [Hsp70-PC (1) + DSP (2)] relative to that observed
when the DSP peptide is used in both the first and second
iDCs loaded with Hsp70 or Hsp70-PC from MDA-MB-231  cells can prime human lymphocytes to respond to MDA-MB- 231 cell extracts Figure 4
iDCs loaded with Hsp70 or Hsp70-PC from MDA-
MB-231 cells can prime human lymphocytes to 
respond to MDA-MB-231 cell extracts. Purified Hsp70, 
Hsp70-PCs from MDA-MB-231 cells or soluble protein 
extracts from MDA-MB-231 tumour cells (TC) were incu-
bated with iDCs isolated from two healthy female blood 
donors (Donor A; grey bars. Donor B; black bars). The iDCs 
were incubated [first stimulation (1)] with CD14- PBMCs 
from the same donor. The cells were cultured for 10 days 
and then, re-incubated [second stimulation (2)] with iDCs 
from the same donor loaded with TC. Supernatants were 
tested for IFN-γ (pg/mL) production by ELISA. The label 
'Hsp70-PC(1)/TC(2)' in this figure refers to IFN-γ production 
by CD14-PBMCs following first and second incubations with 
iDCs loaded with Hsp70-PC and TC respectively. Other 
labels follow a similar paradigm.Journal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
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stimulations [DSP (1) +DSP (2)]. When cells were stimu-
lated with Hsp70, depleted of the associated peptides in
the first stimulation and then challenged with iDCs
loaded with the DSP peptide in the second stimulation,
IFN-γ secretion is also observed however to a lesser degree
than that observed with Hsp-70-PC [Hsp70 (1) +DSP
(2)]. Reiterating the previous finding (Fig. 3A), a single
stimulation of CD14- PBMCs with the DSP peptide is not
sufficient to elicit detectible IFN-γ production [DSP (1)],
nor was IFN-γ produced if PBMCs were incubated with
iDCs stimulated by LPS alone in the first stimulation and
then challenged with iDCs loaded with the DSP peptide in
the second stimulation (data not shown).
Taken together, our data suggest that the mimic peptide
DSP resembles immunogenic peptides and/or protein
components from both tumourigenic and non-tumouri-
genic breast cell lines and has the ability to stimulate
human CD14- PBMCs in vitro. Furthermore, the DSP pep-
tide may structurally resemble peptides complexed with
Hsp70.
Discussion
Phage display libraries, since their discovery in 1990 [42],
have been used to identify high affinity ligands to a variety
of molecules small and large. Recently, Tiwari and col-
leagues [28] have used two different peptide phage dis-
play libraries to identify potential peptides that mimic the
antibody-binding epitopes of the extracellular domain of
HER-2/neu antigen. Employing anti-HER-2/neu mono-
clonal antibodies as a bait and four rounds of bio pan-
ning, the three selected peptides were able to elicit
iDCs loaded with Hsp70 or Hsp70-PC from MDA-MB-231  cells can prime human lymphocytes to respond to synthetic  DSP peptide Figure 6
iDCs loaded with Hsp70 or Hsp70-PC from MDA-
MB-231 cells can prime human lymphocytes to 
respond to synthetic DSP peptide. IDCs from two 
healthy female donors (Donor A; grey bars. Donor B; black 
bars), were incubated with either Hsp70 or Hsp70-PCs from 
MDA-MB-231 cells or the synthetic DSP peptide. The iDCs 
were then incubated with CD14- PBMCs from the same 
donor. [First stimulation (1)]. The cells were cultured for 10 
days and then, incubated with a second batch of iDCs loaded 
with the synthetic peptide DSP [Second stimulation (2)]. The 
supernatants were assayed for IFN-γ production (pg/mL). 
The label 'Hsp70-PC(1)/DSP(2)' refers to IFN-γ production 
by CD14-PBMCs following first and second stimulations with 
iDCs loaded with Hsp70-PC and the DSP peptide respec-
tively. Other labels in the figure follow a similar paradigm.
iDCs loaded with DSP or TMG can prime human lym- phocytes to respond to MDA-MB-231 cell extracts Figure 5
iDCs loaded with DSP or TMG can prime human 
lymphocytes to respond to MDA-MB-231 cell 
extracts. iDCsfrom two healthy female blood donors 
(Donor A; grey bars. Donor B; black bars), were incubated 
with the peptides DSP or TMG, or cell extracts from MDA-
MB-231 tumour cells (TC) [A] or MCF-12A non-tumour 
cells (NTC) [B]. The loaded iDCs were incubated [First 
stimulation (1)] with CD14- PBMCs from the same individual. 
The cells were cultured for 10 days and then, incubated for a 
second time [Second stimulation (2)] with iDCs loaded with 
either TC [A] or NTC [B]. Supernatants were assayed for 
IFN-γ (pg/mL) production by ELISA. The label 'DSP(1)/TC(2)' 
refers to IFN-γ production by CD14-PBMCs following first 
and second incubations with iDCs loaded with DSP peptide 
and TC respectively. Other labels follow a similar paradigm.Journal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
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humoral immune responses in mice and to inhibit the
binding of the bait to HER-2/neu [28] antigen, thus illus-
trating that synthetic peptide mimics can elicit immune
stimulatory activities.
The primary aim of this study was to test a "proof of prin-
ciple", that functional synthetic mimics of native Hsp70-
PCs could be identified by using two step bio-panning of
random peptide phage display libraries. Previous studies
have shown that Hsp-PCs from mice and humans can
induce specific T-cell responses [7,21]. The mimic pep-
tides, in principle, should structurally resemble the
Hsp70-PCs used as the initial bait and may have func-
tional properties similar to Hsp70-PCs such as the ability
to stimulate T-cells. The Hsp70-PCs preparation used in
this study was obtained by affinity selection on an ADP-
agarose column. Hsp70-PCs, isolated by this method,
have been shown to contain a wide array of peptides and
to possess immune-stimulatory activity [7,43]. Thus, the
starting material for the bio-panning was the pool of pep-
tides complexed with Hsp70. This approach circumvents
the need for the purification of individual peptides from
the Hsp70-PC fraction and selects for the abundant ones.
Similar bio-panning approaches have proved successful in
identifying tissue-specific peptide ligands [(25); see ref.
[37] for a review].
A variety of phages displaying unique peptides were iden-
tified by the bio-panning method. There appeared to be a
high degree of enrichment of specific sequences following
four rounds of bio-panning; certain peptides selected were
common to at least two bio-pannings and one of the pep-
tides (TMG) was recovered in all three bio-pannings. The
diversity of peptides identified may be in part due to the
complexity of the Hsp70-PCs fraction used as the bait. The
peptide TMG was selected in three independent bio-pan-
ning experiments, suggesting that the motif recognised by
TMG may be consistently abundant in the three pools of
Hsp70-PCs.
Three of the 'recogniser' peptides, identified in multiple
bio-panning experiments, were then used in a reverse bio-
panning experiment to identify sequences that interact
with these peptides. Two of these recogniser peptides,
NNY and IER, selected a wide variety of binders, one of
which, SVS, was common between the two selected pools.
Subsequent bio-panning experiments with an unrelated
peptide bait, consistently selected the SVS peptide
(Arnaiz, James and Bond unpublished data). Interest-
ingly, this same phage peptide had been identified in two
unrelated bio-pannings for peptides interacting with (i)
murine cerebellar granular neurons and (ii), a Japanese
encephalitis virus envelope protein neutralizing antibody
[40,41]. The consistent selection of SVS with unrelated
baits perhaps suggests that this peptide may recognise
some common structure among all baits, for example the
peptide bond backbone. Unlike the peptides NNY and
IER, the TMG selected only a single displayed peptide after
four rounds of bio-panning. Due to the high degree of
selectivity of the TMG peptide and the fact that this pep-
tide was identified in three independent bio-panning
experiments, we focused our subsequent analysis on this
TMG-DSP 'recogniser-mimic' pair.
The ability of the synthetic peptides to activate lym-
phocytes was examined using an in vitro assay. The results
show that lymphocytes were stimulated but required two
consecutive iDC-mediated exposures to either the mimic
peptide DSP or the recogniser peptide TMG. Unlike LPS,
these peptides did not stimulate iDCs to produce IL-12.
Therefore, we can conclude that (a) the activation of lym-
phocytes must be dependent upon the uptake of the pep-
tide by iDCs and its representation to lymphocytes and
(b) it is not the result of any adjuvant-like contaminant
present in the peptide preparation. The DSP peptide
showed lymphocyte stimulatory activity while, another
peptide WHK produced no stimulation. Surprisingly, we
did observe lymphocyte stimulation with the recogniser
peptide TMG. The reason why lymphocyte activation was
not limited to only mimics is currently unclear. The
observed differences in effectiveness between the peptides
may be reflective of the different proteolytic processing
and/or the preference of the different HLA class I mole-
cules for presentation of 9-mer peptides with specific
amino acids in anchor positions. A search of the compre-
hensive database SYFPEITHI [44] for HLA class I ligands
with the peptide sequences revealed a higher likelihood
for DSP and TMG than WHK to be presented by the HLA
class I molecule (data not shown). Furthermore, based on
our model of recognisers and mimics described above, it
is quite possible that peptides structurally equivalent to
recogniser peptides may also be present in the pool of
Hsp70-PCs, for example, the EGF receptor (a possible 'rec-
ogniser' molecule) is activated by autocrine or paracrine
growth factor loops and is known to be over-expressed in
at least 50% of all epithelial malignancies [45] as is its lig-
and, EGF, (a possible 'mimic' molecule). Supporting this
view, we find that both TMG and DSP peptides but not
WHK specifically bind to MDA-MB-231 cells indicating
that either peptide can interact with cellular components
within these cells (Arnaiz and Bond, unpublished results).
To determine if the DSP peptide represents a mimic of
true tumour antigens present in tumour cells and in par-
ticular tumour antigens in the Hsp70-PCs pool, we
employed an assay in which lymphocytes are stimulated
in two consecutive rounds with different antigen pools.
We find that tumour cell extracts contain certain antigens
in common with those present in the Hsp70-PCs fraction
as they successfully stimulate T-cells previously primedJournal of Immune Based Therapies and Vaccines 2006, 4:2 http://www.jibtherapies.com/content/4/1/2
Page 10 of 12
(page number not for citation purposes)
with Hsp70-PCs from the same tumour cells. Addition-
ally, we observe that Hsp70 alone, in the absence of any
associated peptides, can prime T-cells to respond to
tumour cell extracts. Thus Hsp70 in addition to chaperon-
ing peptides into the antigen processing pathway of iDC,
may also trigger IFN-γ production in a similar way to that
of LPS [46-49]. These findings are in agreement with pre-
vious data showing that Hsp70 can enhance the ability of
APCs for antigen uptake [50,51] and can activate T cells in
vitro an in vivo [10,52]. Therefore, one could envisage a
pool of antigens (peptides) being chaperoned by adjuvant
molecules such as Hsp70 which can also facilitate their
uptake by the APCs through Hsp-specific receptors (e.g.,
CD91) in the case of tissue damage or necrosis. These pep-
tides may be then re-presented to T-cells, through the
MHC class I antigen processing pathway (cross-priming).
Thus, the reconstitution of peptides with Heat shock pro-
teins such as Hsp70, might be an important strategy to
ensure an enhancement of the T-cell response to peptides
[16,53].
Using the same technique, we also show that the DSP pep-
tide resembles antigens present in total cell extracts from
either tumourigenic (MDA-MB-231) or non-tumouri-
genic (MCF-12A) breast carcinoma cell lines. Thus, the
DSP peptide may mimic a common antigen in both cell
lines. The TMG peptide showed lower levels of lym-
phocyte stimulation following a second exposure to either
extracts from MDA-MB-231 or MCF-12A cell lines. We
also show that lymphocytes incubated initially with iDCs
loaded with Hsp70-PCs can be re-stimulated with iDCs
loaded the DSP peptide, again suggesting that this peptide
resembles antigenic peptides associated with the Hsp70 in
these cell lines.
Conclusion
In conclusion, we have developed a bio-panning
approach to enrich from phage display libraries potential
peptide mimics of Hsp70-PCs and an in vitro lymphocyte
activation assay to validate their potential as tumour spe-
cific antigen mimics. Such peptides could be further mod-
ified or combined with other molecules to develop
potential tumour vaccines. In this initial study we have
identified two peptides with lymphocyte stimulatory
activity. We envisage further adjustments to the bio-pan-
ning protocol such as pre-adsorbing the phage display
library to a non-tumourigenic Hsp70-PC fraction to
enrich for true tumour-specific recogniser peptides and/or
the use of tandem mass spectroscopy to directly sequence
and identify the peptides associated with Hsp70-PCs. In
the latter case, their synthetic equivalents can be tested
directly in T-cell stimulation. High throughput assays
could be developed to relatively quickly screen large num-
bers of synthetic recogniser/mimic peptides identified
through the strategies described here. Such mimics could
be further modified to increase their immunological effec-
tiveness either inherently at the sequence level or by using
a cocktail of selected mimics for a given tumour based on
their IFN-γ response. Furthermore, the essential concept
of the screening strategy can be applied to many other
potential drug and biomarker discovery applications.
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